Open Access
Math. Model. Nat. Phenom.
Volume 19, 2024
Article Number 1
Number of page(s) 31
Section Population dynamics and epidemiology
Published online 12 January 2024
  1. S. Bernard and F. Crauste, Optimal linear stability condition for scalar differential equations with distributed delay. Discrete Continuous Dyn. Syst. B 20 (2015) 1855. [CrossRef] [MathSciNet] [Google Scholar]
  2. A. Besse, G.D. Clapp, S. Bernard, F.E. Nicolini, D. Levy and T. Lepoutre, Stability analysis of a model of interaction between the immune system and cancer cells in chronic myelogenous leukemia. Bull. Math. Biol. 80 (2018) 1084–1110. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  3. G.D. Clapp, T. Lepoutre, R. El Cheikh, S. Bernard, J. Ruby, H. Labussière-Wallet, F.E. Nicolini and D. Levy, Implication of the autologous immune system in bcr–abl transcript variations in chronic myelogenous leukemia patients treated with imatinib. Cancer Res. 75 (2015) 4053–4062. [CrossRef] [PubMed] [Google Scholar]
  4. R.E. Clark, F. Polydoros, J.F. Apperley, D. Milojkovic, K. Rothwell, C. Pocock, J. Byrne, H. de Lavallade, W. Osborne, L. Robinson, S.G. O’Brien, L. Read, L. Foroni and M. Copland, De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (destiny): a non-randomised, phase 2 trial. Lancet Haematol. 6 (2019) e375–e383. [CrossRef] [Google Scholar]
  5. M.W.N. Deininger, J.M. Goldman and J.V. Melo, The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343–3356. [CrossRef] [PubMed] [Google Scholar]
  6. A.C. Fassoni, I. Roeder and I. Glauche, To cure or not to cure: consequences of immunological interactions in cml treatment. Bull. Math, Biol. 81 (2019) 2345–2395. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  7. A. Gratwohl, M. Pfirrmann, A. Zander, N. Kröger, D. Beelen, J. Novotny, C. Nerl, C. Scheid, K. Spiekermann, J. Mayer, et al., Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 30 (2016) 562–569. [CrossRef] [PubMed] [Google Scholar]
  8. T. Hähnel, C. Baldow, A.C. Fassoni, J. Guilhot, F. Guilhot, S. Saussele, S. Mustjoki, S. Jilg, P.J. Jost, S. Dulucq, F.-X. Mahon, I. Roeder and I. Glauche, Inferring immunological control mechanisms from TKI dose alterations in cml patients. bioRxiv, 2019. [Google Scholar]
  9. T. Hähnel, C. Baldow, J. Guilhot, F. Guilhot, S. Saussele, S. Mustjoki, S. Jilg, P.J. Jost, S. Dulucq, F.-X. Mahon, et al., Model-based inference and classification of immunologic control mechanisms from TKI cessation and dose reduction in patients with cml. Cancer Res. 80 (2020) 2394–2406. [CrossRef] [PubMed] [Google Scholar]
  10. R. Hehlmann, U. Berger, M. Pfirrmann, H. Heimpel, A. Hochhaus, J. Hasford, H.-J. Kolb, T. Lahaye, O. Maywald, A. Reiter, et al., Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109 (2007) 4686–4692. [CrossRef] [PubMed] [Google Scholar]
  11. A. Hochhaus, M. Baccarani, R.T. Silver, C. Schiffer, J.F. Apperley, F. Cervantes, R.E. Clark, J.E. Cortes, M. Deininger, F. Guilhot, et al., European leukemianet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34 (2020) 966–984. [CrossRef] [PubMed] [Google Scholar]
  12. M. Ilander, U. Olsson-Straömberg, H. Schlums, J. Guilhot, O. Brüack, H. Lähteenmäki, T. Kasanen, P. Koskenvesa, S. Söaderlund, M. Höglund, et al., Increased proportion of mature nk cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31 (2017) 1108–1116. [CrossRef] [PubMed] [Google Scholar]
  13. P. Jain, H.M. Kantarjian, A. Ghorab, K. Sasaki, E.J. Jabbour, G. Nogueras Gonzalez, R. Kanagal-Shamanna, G.C. Issa, G. Garcia-Manero, D. Kc, et al., Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer 123 (2017) 4391–4402. [CrossRef] [PubMed] [Google Scholar]
  14. F.-X. Mahon, D. Réa, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Etienne, J. Reiffers and P. Rousselot, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (stim) trial. Lancet Oncol. 11 (2010) 1029–1035. [CrossRef] [Google Scholar]
  15. F. Michor, T.P. Hughes, Y. Iwasa, S. Branford, N.P. Shah, C.L. Sawyers and M.A. Nowak, Dynamics of chronic myeloid leukaemia. Nature 435 (2005) 1267–1270. [CrossRef] [PubMed] [Google Scholar]
  16. K.-J.E.R. Nagel, One-parameter Semigroups for Linear Evolution Equations, Vol. 194. Springer-Verlag New York (2000). [Google Scholar]
  17. D. Rea, G. Henry, Z. Khaznadar, G. Etienne, F. Guilhot, F. Nicolini, J. Guilhot, P. Rousselot, F. Huguet, L. Legros, et al., Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the immunostim study. Haematologica 102 (2017) 1368–1377. [CrossRef] [PubMed] [Google Scholar]
  18. I. Roeder, M. Horn, I. Glauche, A. Hochhaus, M. C. Mueller and M. Loeffler, Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12 (2006) 1181–1184. [CrossRef] [PubMed] [Google Scholar]
  19. S. Saussele, J. Richter, A. Hochhaus and F. Mahon, The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30 (2016) 1638–1647. [CrossRef] [PubMed] [Google Scholar]
  20. G. Stépán, Retarded Dynamical Systems: Stability and Characteristic Functions. Longman Scientific & Technical (1989). [Google Scholar]
  21. A. Yong and A. Hughes, Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front. Immunol. 8 (2017). [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.